Jump to Main Content
Electrochemical magnetic microbeads-based biosensor for point-of-care serodiagnosis of infectious diseases
- Cortina, María E., Melli, Luciano J., Roberti, Mariano, Mass, Mijal, Longinotti, Gloria, Tropea, Salvador, Lloret, Paulina, Serantes, Diego A. Rey, Salomón, Francisco, Lloret, Matías, Caillava, Ana J., Restuccia, Sabrina, Altcheh, Jaime, Buscaglia, Carlos A., Malatto, Laura, Ugalde, Juan E., Fraigi, Liliana, Moina, Carlos, Ybarra, Gabriel, Ciocchini, Andrés E., Comerci, Diego J.
- Biosensors & bioelectronics 2016 v.80 pp. 24-33
- Chagas disease, Protozoa, antigens, bacteria, biomarkers, biosensors, bovine brucellosis, early diagnosis, electrochemistry, enzyme-linked immunosorbent assay, fluorescence, foot-and-mouth disease, human diseases, humans, microbial detection, pathogens, polymerase chain reaction, serodiagnosis, viruses
- Access to appropriate diagnostic tools is an essential component in the evaluation and improvement of global health. Additionally, timely detection of infectious agents is critical in early diagnosis and treatment of infectious diseases. Conventional pathogen detection methods such as culturing, enzyme linked immunosorbent assay (ELISA) or polymerase chain reaction (PCR) require long assay times, and complex and expensive instruments making them not adaptable to point-of-care (PoC) needs at resource-constrained places and primary care settings. Therefore, there is an unmet need to develop portable, simple, rapid, and accurate methods for PoC detection of infections. Here, we present the development and validation of a portable, robust and inexpensive electrochemical magnetic microbeads-based biosensor (EMBIA) platform for PoC serodiagnosis of infectious diseases caused by different types of microorganisms (parasitic protozoa, bacteria and viruses). We demonstrate the potential use of the EMBIA platform for in situ diagnosis of human (Chagas disease and human brucellosis) and animal (bovine brucellosis and foot-and-mouth disease) infections clearly differentiating infected from non-infected individuals or animals. For Chagas disease, a more extensive validation of the test was performed showing that the EMBIA platform displayed an excellent diagnostic performance almost indistinguishable, in terms of specificity and sensitivity, from a fluorescent immunomagnetic assay and the conventional ELISA using the same combination of antigens. This platform technology could potentially be applicable to diagnose other infectious and non-infectious diseases as well as detection and/or quantification of biomarkers at the POC and primary care settings.